Tristen Moors

Tristen Moors has been working in clinical operations and development for 20+ years. She has been fortunate to focus the majority of her clinical operations career in rare disease, including urea cycle disorders (UCDs), X-linked myotubular myopathy (XLMTM), and thymidine kinase 2 deficiency (TK2d). She most recently headed clinical operations at Modis Therapeutics, a wholly owned subsidiary of Zogenix, which focuses on the development of therapies to treat mitochondrial diseases. Ms. Moors received her MS in marine science from the University of California, Santa Cruz and BS in biology from Santa Clara University.